Table of Contents
FREEHOLD, N.J. – Armas Pharmaceuticals announces the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market. This key product has been unavailable for more than two years, and its return underscores Armas' commitment to providing critical medications with a focus on consistent supply and sustainability.
Lidocaine Jelly 2% is a topical anesthetic used in various medical applications, including urological and endoscopic procedures, to provide localized pain relief. Its reintroduction is expected to address a significant gap in the market and meet the needs of healthcare providers nationwide.
"Our mission at Armas Pharmaceuticals is to ensure that essential medications remain consistently available to the healthcare community," said Joe Niemi, president and CEO of Armas Pharmaceuticals. "The return of Lidocaine Jelly 2% 30mL represents our ongoing commitment to supply chain sustainability and our ability to respond to critical product needs in the market. We will continue to expand our portfolio with a focus on reliability, quality, and patient care."
Armas Pharmaceuticals continues to strengthen its presence in the pharmaceutical industry by offering a robust and growing portfolio of high-quality products. With a steadfast commitment to innovation and supply chain security, the company remains dedicated to addressing critical healthcare needs in the U.S. market.
For more information on Lidocaine Jelly 2% 30mL and other Armas Pharmaceuticals products, please visit www.armaspharma.com.
